Superworth

Lantheus price to free cash flow LNTH

Market value divided by free cash flow over the last twelve months, since 2016.

Today, Nov 2, 2026
16.9×
10-year median
17.5×
Against its 10-year history
45th
percentile: 0 is its lowest day, 100 its highest
10-year range
7.0× to 427×
Peer median
27.7×

Lantheus' price to free cash flow is 16.9× as of Nov 2, 2026.

That is below its ten-year median of 17.5×, close to the middle of its last ten years.

Over that time it ranged from 7.0× in Apr 2020 to 427× in Jul 2021.

The median for 10 diagnostics and research stocks of a similar size is 27.7×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far16.9×10.3×19.0×
202510.7×7.2×15.1×
202413.8×11.5×28.0×
202368.4×19.4×281×
202220.4×20.2×127×
202166.9×39.9×427×
202036.3×7.0×40.0×
201915.7×15.7×25.5×
201815.1×14.6×21.9×
201719.0×7.4×21.0×
20167.7×6.1×9.5×

Against its peers

Companies in Medical - Diagnostics & Research nearest Lantheus' size, closest first, today.

CompanyPrice to free cash flow
LNTHLantheus16.9×
BLLNBillionToOne157×
CAICaris Life Sciences73.2×
CDNACareDxn/m
BIOBio-Rad Laboratories27.7×
VCYTVeracyte23.7×
RVTYRevvity30.3×
MEDPMedpace25.6×
DGXQuest Diagnostics20.0×
LHLabcorp25.0×
MTDMettler-Toledo International39.6×
Peer median27.7×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Lantheus

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.